SHR 0302

Drug Profile

SHR 0302

Alternative Names: SHR0302

Latest Information Update: 20 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2016 Jiangsu HengRui Medicine initiates a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Tablet) (NCT02892370)
  • 24 Jan 2016 Jiangsu HengRui Medicine plans a phase I trial for Rheumatoid arthritis in China (NCT02665910)
  • 01 Apr 2015 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (PO) (NCT02423538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top